SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Mumtaz Mahal

PatientMumtaz Mahal
Date of birth1988-04-27
IdentifiersMRN HR-RE006-SYN; SSN (made up) 000-06-7184
Document date2026-04-14
AuthorFarzana Qureshi-Lindholm, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Prenatal visit at 27 weeks. [S]

History of Present Illness

Mumtaz Mahal returns at 27 weeks 2 days. The cystitis three weeks ago settled within two days of starting nitrofurantoin, and the culture grew Escherichia coli sensitive to it; she finished the 5-day course. She has no urinary symptoms now. She feels well, with good energy, and the baby moves often. She takes aspirin and folic acid. She has no headache, visual change, swelling of the face or hands, abdominal pain, contractions, bleeding, or leaking fluid. Her family plans to travel for about six weeks, starting next week, mostly by road, and she intends to go with them. [S]

ElementDetail
CystitisResolved; culture Escherichia coli, sensitive to nitrofurantoin; course completed
EnergyGood since the second iron dose
Fetal movementFrequent
TravelAbout six weeks of road travel planned from next week

Review of Systems

SystemResultFinding
ConstitutionalNegativeWell; energy good
CardiovascularNegativeNo breathlessness, palpitations, or leg swelling
NeurologicalNegativeNo headache or visual change
GenitourinaryNegativeNo urinary symptoms, bleeding, or leaking fluid
PsychiatricNegativeMood steady; EPDS 6

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Folic acid 0.4 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-06activeS
Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other dayOne tablet every other morning with water or orange juice, apart from tea and calciumOral route2026-01-06 to 2026-02-03completedS
Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtimeOne tablet by mouth at bedtime until deliveryOral route2026-01-06activeS
Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily for 5 daysOne capsule twice daily with food for 5 daysOral route2026-03-24 to 2026-03-29completedS
Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (first of two doses)Single infusion; two doses in total, four weeks apartIntravenous route2026-02-03 to 2026-02-03completedS
Ferric carboxymaltose 750 mg in 250 mL 0.9% sodium chloride, intravenous infusion over 15 minutes (second of two doses)Single infusion; two doses in total, four weeks apartIntravenous route2026-03-03 to 2026-03-03completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-14Body height157cmS
2026-04-14Body weight64.6kgS
2026-04-14Body mass index (BMI) [Ratio]26.2kg/m2S
2026-04-14Systolic blood pressure108mm[Hg]S
2026-04-14Diastolic blood pressure68mm[Hg]S
2026-04-14Heart rate86/minS
2026-04-14Respiratory rate16/minS
2026-04-14Body temperature36.7CelS
2026-04-14Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-14Hemoglobin [Mass/volume] in Blood11.4g/dL10.5-15 g/dLNormalS
2026-04-14Ferritin [Mass/volume] in Serum or Plasma110ng/mL30-150 ng/mLNormalS
2026-04-14Platelets [#/volume] in Blood by Automated count23210*3/uL150-400 10*3/uLNormalS
2026-04-14Glucose [Mass/volume] in Serum or Plasma --1 hour post 50 g glucose PO128mg/dL<=139 mg/dLNormalS
2026-04-14Total score [EPDS]6{score}S

Physical Exam

Vital signs recorded on 2026-04-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell
AbdomenFundal height 27 cm; non-tender
FetalFetal heart 144 per minute by Doppler
ExtremitiesNo edema; calves soft and non-tender
Urine dipstickProtein negative; leukocytes and nitrite negative

Problems

ProblemClinical statusVerificationCodeProvenance
Fourteenth pregnancy at 37 (gravida 14, para 13), single live intrauterine pregnancy dated by ultrasound at 13 weeks 2 days; estimated due date July 12activeconfirmed O09.529S — Synthetic modern prenatal care anchored to her documented fourteenth pregnancy; the dates are synthetic.
Grand multiparity: thirteen previous vaginal births, no cesarean or other uterine surgery; seven living childrenactiveconfirmed O09.40S — Synthetic modern problem anchored to her documented thirteen earlier births.
Short interpregnancy interval: conception about five and a half months after her last birthactiveconfirmed O09.899S — Synthetic modern problem anchored to the documented fourteen months between her last two births.
Iron deficiency anemia in pregnancy: hemoglobin 10.1 g/dL, MCV 76 fL, ferritin 9 ng/mLactiveconfirmed O99.019S — Synthetic finding; repeated pregnancies close together deplete iron. It echoes no documented diagnosis.
Acute cystitis in pregnancy at 24 weeks: dysuria and frequency, no fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; treated and resolvedresolvedconfirmed O23.12S — Synthetic intercurrent infection at an unscheduled visit; common in pregnancy and in multiparous women. It echoes no documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure and urine proteinEvery prenatal visitCompleted today108/68 mmHg; urine protein negative
ExaminationFetal heart and fundal heightEvery prenatal visitCompleted todayFetal heart 144 per minute; fundal height 27 cm
ExaminationWeight gainEvery prenatal visitCompleted today64.6 kg, up 6.0 kg since intake
LaboratoryHemoglobin and ferritinAt intake, four weeks after starting treatment, at 24 to 28 weeks, and before deliveryCompleted todayHemoglobin 11.4 g/dL and ferritin 110 ng/mL
LaboratoryGestational diabetes screen (one-hour 50 g glucose challenge)At 24 to 28 weeksCompleted today128 mg/dL, below the 140 mg/dL threshold
LaboratoryUrine culture as a test of cure after cystitisOne to two weeks after treatmentOrderedSent today, two weeks after the course ended
LaboratoryAntibody screen and anti-D at 28 weeksAt 28 weeks for RhD-negative patientsNot indicatedRhD positive with a negative antibody screen at intake
Medication safetyTdap vaccineOnce at 27 to 36 weeks in every pregnancyCompleted todayGiven today
Medication safetyLow-dose aspirinDaily from 12 to 16 weeks until delivery; review at every visitCompleted todayTaken nightly; no bruising or bleeding
SurveyPerinatal mood screen (EPDS)Each trimesterCompleted today6; item 10 scored 0
Self-managementTravel planningBefore any travel in pregnancyCompleted todaySix weeks of road travel planned; records given; care to be arranged where she stays
Self-managementPostpartum hemorrhage risk assessment and birth planAt intake, in the third trimester, and on admission for birthUp to dateAnemia corrected; grand multiparity remains; detailed plan at the next visit

Goal progress:

Immunizations given today: Tdap vaccine in pregnancy, 27 weeks [S]

Guideline basis: Pregnancy at Age 35 Years or Older: ACOG Obstetric Care Consensus No. 11 (2022); Anemia in Pregnancy: ACOG Practice Bulletin, Number 233 (2021); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021); ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus (2018); ACOG Committee Opinion No. 746: Air Travel During Pregnancy (2018); Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America (2019)

Follow-up: Prenatal visits at 30 and 32 weeks where she is staying, then here on her return. Next scheduled visit 2026-06-02: prenatal visit at 34 weeks: growth scan, postpartum hemorrhage risk assessment, delivery plan, and contraception counseling. [S]